In relation to patients with no BRCA1/2 pathogenic or likely-pathogenic variants, niraparib has been present in therapy since the beginning of Period II, which indirectly proves that HRD patients also had the opportunity to use PARPis. Here, BRCA1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.